Profile data is unavailable for this security.
About the company
JW (Cayman) Therapeutics Co Ltd is a company primarily engaged in research and development, manufacturing, and marketing of cellular immunotherapy products. The Company has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. The Company’s main product, Carteyva, is an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) cell immunotherapy product independently developed by the Company based on a CAR-T cell process platform of Juno (a Bristol Myers Squibb company). The Company mainly conducts its business in the domestic market.
- Revenue in HKD (TTM)190.72m
- Net income in HKD-692.44m
- Incorporated2017
- Employees323.00
- LocationJW (Cayman) Therapeutics Co LtdNo 225 Meisheng RoadPilot Free Trade Zone, 4f, Building 42SHANGHAI KY1-1104ChinaCHN
- Websitehttps://www.jwtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sirnaomics Ltd | 0.00 | -637.57m | 276.94m | 90.00 | -- | 145.61 | -- | -- | -8.40 | -8.40 | 0.00 | 0.0217 | 0.00 | -- | -- | 0.00 | -110.32 | -- | -136.58 | -- | -- | -- | -- | -- | -- | -3.25 | -- | -- | -- | -- | 10.88 | -- | -- | -- |
Clover Biopharmaceuticals Ltd | 31.87m | -975.26m | 290.54m | 323.00 | -- | -- | -- | 9.12 | -0.782 | -0.782 | 0.0255 | -0.7081 | 0.0119 | 0.014 | 98.80 | 82,354.02 | -36.27 | -- | -405.86 | -- | 54.86 | -- | -3,060.03 | -- | 0.4426 | -- | -- | -- | -- | -- | 94.35 | -- | -- | -- |
Antengene Corp Ltd | 61.84m | -584.00m | 371.19m | 178.00 | -- | 0.3387 | -- | 6.00 | -0.9468 | -0.9468 | 0.1002 | 1.62 | 0.035 | 0.6597 | 1.57 | 307,643.00 | -33.06 | -53.57 | -37.16 | -58.94 | 84.84 | -- | -944.43 | -1,987.01 | 5.66 | -23.74 | 0.1663 | -- | -57.97 | -- | 3.38 | -- | 202.03 | -- |
Kintor Pharmaceutical Ltd | 0.00 | -1.01bn | 411.70m | 175.00 | -- | 0.9533 | -- | -- | -2.36 | -2.36 | 0.00 | 0.965 | 0.00 | 0.1411 | -- | 0.00 | -70.41 | -50.15 | -87.57 | -58.43 | -- | -27.62 | -- | -10,511.41 | 1.56 | -111.48 | 0.3788 | -- | -- | -- | -11.15 | -- | -32.49 | -- |
HighTide Therapeutics Inc | 0.00 | -662.29m | 458.15m | 66.00 | -- | 0.6954 | -- | -- | -1.42 | -1.42 | 0.00 | 1.28 | 0.00 | -- | -- | 0.00 | -87.01 | -- | -118.34 | -- | -- | -- | -- | -- | -- | -- | 0.0404 | -- | -- | -- | -393.76 | -- | -- | -- |
JW (Cayman) Therapeutics Co Ltd | 190.72m | -692.44m | 568.78m | 323.00 | -- | 0.3457 | -- | 2.98 | -1.68 | -1.68 | 0.4624 | 3.96 | 0.0747 | 1.87 | 11.48 | 479,201.10 | -27.11 | -39.77 | -31.71 | -44.00 | 50.40 | -- | -363.06 | -1,316.81 | 2.76 | -- | 0.2043 | -- | 19.32 | -- | 9.23 | -- | -19.87 | -- |
Brii Biosciences Ltd | 0.00 | -292.76m | 752.51m | 95.00 | -- | 0.2384 | -- | -- | -0.4012 | -0.4012 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -8.89 | -- | -9.01 | -- | -- | -- | -- | -- | -- | -- | 0.007 | -- | -98.80 | -- | 63.90 | -- | -- | -- |
Genor Biopharma Holdings Ltd | 15.96m | -579.57m | 857.97m | 28.00 | -- | 0.7242 | -- | 53.76 | -1.14 | -1.14 | 0.0314 | 2.28 | 0.0093 | 0.0178 | 0.2277 | 153,448.70 | -33.87 | -55.46 | -39.06 | -63.73 | 97.59 | 66.56 | -3,638.27 | -14,819.18 | 5.73 | -- | 0.003 | -- | -100.00 | -- | 7.65 | -- | -48.85 | -- |
Sunho Biologics Inc | -100.00bn | -118.33m | 900.83m | -- | -- | 1.49 | -- | -- | -0.8784 | -0.8784 | -- | 3.86 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.77 | -4,626.67 | 0.0516 | -- | -- | -- | -155.25 | -- | -- | -- |
Data as of Sep 23 2024. Currency figures normalised to JW (Cayman) Therapeutics Co Ltd's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
Dimensional Fund Advisors LPas of 31 May 2024 | 1.44m | 0.35% |
Norges Bank Investment Managementas of 31 Dec 2023 | 917.99k | 0.22% |
Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 300.00k | 0.07% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 277.00k | 0.07% |
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 200.00k | 0.05% |
Dimensional Fund Advisors Ltd.as of 30 Jun 2024 | 108.17k | 0.03% |
SSgA Funds Management, Inc.as of 05 Sep 2024 | 97.85k | 0.02% |
DFA Australia Ltd.as of 31 Jul 2024 | 1.83k | 0.00% |
JPMorgan Asset Management (UK) Ltd.as of 31 Dec 2023 | 0.00 | 0.00% |
Atlantis Investment Management Ltd. /Hong Kong/as of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.